Anti-Tat immunity defines CD4⁺ T-cell dynamics in people living with HIV on long-term cART.

ABSTRACT:

Background

Low-level HIV viremia originating from virus reactivation in HIV reservoirs is often present in cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery of CD4⁺ T cells. The HIV-1 Tat protein is released in the extracellular milieu and activates immune cells and latent HIV, leading to virus production and release. However, the relation of anti-Tat immunity with residual viremia, persistent immune activation and CD4⁺ T-cell dynamics has not yet been defined.

Methods

Volunteers enrolled in a 3-year longitudinal observational study were stratified by residual viremia, Tat serostatus and frequency of anti-Tat cellular immune responses. The impact of anti-Tat immunity on low-level virem

SUBMITTER: Tripiciano A 

PROVIDER: S-EPMC8105504 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature